New Charter Seeks to Build Global Support for Tolerance and Religious Freedom
10.12.2019 16:13:00 EET | Business Wire | Press release
This week some of the world’s most respected Islamic scholars, joined by experts from governments, civil society groups and other faiths, will launch a new effort to build global peace, based on tolerance and religious freedom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005594/en/
New Charter Seeks to Build Global Support for Tolerance and Religious Freedom (Photo: AETOSWire)
At the sixth Assembly of the Forum for Promoting Peace in Muslim Societies, in Abu Dhabi, Shaykh Abdullah bin Bayyah, President of the Forum, will inaugurate the charter of the “New Alliance of Virtue”. Its text will be revealed and signed by its first signatories.
The charter aims to elevate religious freedom, cooperation, and tolerance from mere possibilities to necessary ethical commitments and legal obligations, especially in relation to the protection of places of worship whose attacks have threatened freedom of religion in many parts of the world.
This initiative draws direct inspiration from the earliest traditions of Islam.
The original Alliance of Virtue (hilf al-fudul) was established in early 7th century AD (late 1st century BH) Mecca, in the house of Abdullah ibn Judan.
Its purpose was to defend the weak and the innocent against the rapaciousness of those more powerful.
The Prophet of Islam, Mohammad, and the first of the Rightly Guided Caliphs, Abu Bakr, were both present when the Alliance was formed, though it was before Mohammad’s prophethood. He later praised it, saying: “I was present in the house of Ibn Judan when an alliance was formed, and were I to have been called upon by it in Islam, I would have answered its call.”
Last February in Washington D.C., H.E. Shaykh Abdullah bin Bayyah, President of the Forum for Promoting Peace, led a panel of over 200 individuals from the three Abrahamic faiths and others, comprising religious leaders and senior politicians in creating the modern Alliance of Virtue between religions.
The charter of the New Alliance of Virtue follows the model of the original, on a global scale. It brings together those of good-will for the benefit of humanity, an effort across religions to enable its members to live side-by-side in peace and happiness.
The charter doesn’t aim to bridge theological differences, members will instead cooperate based on a common theology of God-given human dignity, seeking virtue for the benefit of all.
Notes for Editors
The Forum for Promoting Peace in Muslim Societies is led by Shaykh Abdullah bin Bayyah, under the patronage of His Highness Sheikh Abdullah bin Zayed Al Nahyan, Minister for Foreign Affairs and International Cooperation. The Forum mines the best global Islamic scholarly expertise for solutions to the challenge of securing global peace. The Forum seeks to extinguish the fire of extremism that has spread throughout the world, with violence driven by erroneous and ill-informed interpretations of Islam. Participants will discuss and devise ways to challenge the extremism and politicisation which causes immense division and suffering.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005594/en/
Contact information
Forum for Promoting Peace in Muslim Societies
Zeshan Zafar, Executive Director, zeshan@peacems.com.
http://www.peacems.com/en/default.aspx
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
